Iptacopan 200mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 200mg

Reference Brands: Fabhalta (USA/EU)

Category: Immune Disorder

Iptacopan is an oral complement factor B inhibitor developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder in which red blood cells are destroyed by the immune system. By inhibiting factor B, Iptacopan prevents the activation of the alternative complement pathway, reducing hemolysis and improving hemoglobin levels. It is taken orally and offers a convenient alternative to intravenous complement inhibitors like eculizumab or ravulizumab.

Product Description:

Iptacopan is an oral inhibitor of complement factor B, the enzyme that drives the alternative complement pathway's amplification loop. Blocking it upstream stops both the intravascular haemolysis caused by the membrane attack complex and the extravascular haemolysis caused by C3 fragments coating red cells — the latter being the residual anaemia that persists in many patients treated with C5 inhibitors.

It is used for paroxysmal nocturnal haemoglobinuria, and in several markets for IgA nephropathy and C3 glomerulopathy, conditions in which uncontrolled alternative pathway activity damages the kidney. In PNH trials it raised haemoglobin substantially in patients who remained anaemic on a C5 inhibitor, and most became transfusion-independent — with the added advantage of an oral capsule twice daily instead of infusions. Blocking complement leaves patients vulnerable to encapsulated bacteria, particularly meningococcus, so vaccination against meningococcal disease is required before treatment, with antibiotic cover where vaccination cannot be completed in time.

Sourcing notes. Originator product, on patent, no generic. Distribution is restricted, with a formal risk programme in the US, and supply depends on documented vaccination. Very high annual cost. Specialist haematology and nephrology centres are the point of use.